Role of gamma knife radiosurgery in the treatment of prolactinomas

. 2019 Aug ; 22 (4) : 411-421.

Jazyk angličtina Země Spojené státy americké Médium print

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid31222579
Odkazy

PubMed 31222579
DOI 10.1007/s11102-019-00971-x
PII: 10.1007/s11102-019-00971-x
Knihovny.cz E-zdroje

PURPOSE: Stereotactic radiosurgery is one of the treatment options for prolactinomas, the most commonly used being Gamma Knife Radiosurgery (GKRS). GKRS is indicated mainly in the treatment of dopamine agonist (DA)-resistant prolactinomas. In our study, we report on our experience in treating prolactinoma patients by GKRS. METHODS: Twenty-eight patients were followed-up after GKRS for 26-195 months (median 140 months). Prior to GKRS, patients were treated with DAs and 9 of them (32.1%) underwent previous neurosurgery. Cavernous sinus invasion was present in 16 (57.1%) patients. Indications for GKRS were (i) resistance to DA treatment (17 patients), (ii) drug intolerance (5 patients), or (iii) attempts to reduce the dosage and/or shorten the length of DA treatment (6 patients). RESULTS: After GKRS, normoprolactinaemia was achieved in 82.1% of patients, out of which hormonal remission (normoprolactinaemia after discontinuation of DAs) was achieved in 13 (46.4%), and hormonal control (normoprolactinaemia while taking DAs) in 10 (35.7%) patients. GKRS arrested adenoma growth or decreased adenoma size in all cases. Two patients (8.3%) developed hypopituitarism after GKRS. Prolactinoma cystic transformation with expansive behaviour, manifested by bilateral hemianopsia, was observed in one patient. CONCLUSIONS: GKRS represents an effective treatment option, particularly for DA-resistant prolactinomas. Normoprolactinaemia was achieved in the majority of patients, either after discontinuation of, or while continuing to take, DAs. Tumour growth was arrested in all cases. The risk of the development of hypopituitarism can be limited if the safe dose to the pituitary and infundibulum is maintained.

Zobrazit více v PubMed

Neurosurgery. 2000 Jan;46(1):138-49; discussion 150-1 PubMed

Stereotact Funct Neurosurg. 1999;72 Suppl 1:88-100 PubMed

Stereotact Funct Neurosurg. 1999;72 Suppl 1:101-10 PubMed

Stereotact Funct Neurosurg. 1999;72 Suppl 1:111-8 PubMed

J Neurosurg. 2000 Dec;93 Suppl 3:10-3 PubMed

J Neurosurg. 2000 Dec;93 Suppl 3:14-8 PubMed

J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61 PubMed

J Neurosurg. 2001 Aug;95(2):285-91 PubMed

J Clin Endocrinol Metab. 2002 Feb;87(2):457-65 PubMed

J Neurosurg. 2002 Sep;97(3):525-30 PubMed

J Neurosurg. 2002 Dec;97(5 Suppl):415-21 PubMed

Neurosurgery. 2003 Feb;52(2):309-16; discussion 316-7 PubMed

Neurosurgery. 2003 Jul;53(1):51-9; discussion 59-61 PubMed

Clin Endocrinol (Oxf). 1992 Dec;37(6):534-41 PubMed

Yonsei Med J. 2003 Aug 30;44(4):602-7 PubMed

Neurosurgery. 2004 Jun;54(6):1385-93; discussion 1393-4 PubMed

J Neurosurg. 2005 Apr;102(4):678-91 PubMed

Clin Endocrinol (Oxf). 2005 Oct;63(4):450-5 PubMed

Clin Endocrinol (Oxf). 2006 May;64(5):588-95 PubMed

Endocr Rev. 2006 Aug;27(5):485-534 PubMed

Neurosurgery. 2006 Aug;59(2):255-66; discussion 255-66 PubMed

N Engl J Med. 2007 Jan 4;356(1):29-38 PubMed

N Engl J Med. 2007 Jan 4;356(1):39-46 PubMed

Eur J Endocrinol. 2007 Feb;156(2):225-31 PubMed

Clin Endocrinol (Oxf). 2009 May;70(5):732-41 PubMed

J Clin Endocrinol Metab. 2008 Dec;93(12):4721-7 PubMed

Eur J Endocrinol. 2009 May;160(5):747-52 PubMed

J Clin Endocrinol Metab. 2009 Sep;94(9):3400-7 PubMed

J Clin Endocrinol Metab. 2010 Jan;95(1):43-51 PubMed

J Neurosurg. 2011 Feb;114(2):303-9 PubMed

Neurosurgery. 2010 Jul;67(1):27-32; discussion 32-3 PubMed

Eur J Endocrinol. 2011 Feb;164(2):169-78 PubMed

J Clin Endocrinol Metab. 2011 Feb;96(2):273-88 PubMed

World Neurosurg. 2010 Jul;74(1):147-52 PubMed

Pituitary. 2013 Mar;16(1):68-75 PubMed

Eur J Endocrinol. 2012 Nov;167(5):651-62 PubMed

QJM. 2013 Jun;106(6):495-504 PubMed

Pituitary. 2015 Jun;18(3):376-84 PubMed

Pituitary. 2015 Dec;18(6):820-30 PubMed

J Neurol Surg Rep. 2015 Jul;76(1):e105-8 PubMed

Drugs. 1995 Feb;49(2):255-79 PubMed

Clin Endocrinol (Oxf). 1994 Dec;41(6):821-6 PubMed

N Engl J Med. 1994 Oct 6;331(14):904-9 PubMed

Drug Saf. 1996 Apr;14(4):228-38 PubMed

J Clin Endocrinol Metab. 1997 Mar;82(3):876-83 PubMed

Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:95-109 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...